Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-Line BiotechNSE:QLINE -1.12%14 Debt-to-EBITDA is 2.57 as of Mar. 2025, which is 7% above its 10-year median of 2.40. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Q-Line Biotech ranks worse than 65.54% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Q-Line Biotech's Debt-to-EBITDA or its related term are showing as below:
NSE:QLINE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.1 Med: 2.4 Max: 2.57
Current: 2.57
During the past 3 years, the highest Debt-to-EBITDA Ratio of Q-Line Biotech was 2.57. The lowest was 2.10. And the median was 2.40.
NSE:QLINE's Debt-to-EBITDA is ranked worse than 65.54% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs NSE:QLINE: 2.57
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Q-Line Biotech Debt-to-EBITDA Related Terms
Q-Line Biotech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Debt-to-EBITDA Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Debt-to-EBITDA
2.10
2.40
2.57
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Debt-to-EBITDA
2.10
2.40
2.57
NSE:QLINE vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Q-Line Biotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Mar. 2025) EBITDA data.
Q-Line Biotech (NSE:QLINE) has a Debt-to-EBITDA of 2.57 as of Mar. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Q-Line Biotech. This is near median its historical median of 2.40. Over the past decade, Q-Line Biotech's Debt-to-EBITDA has ranged from 2.10 to 2.57. According to the industry distribution chart, Q-Line Biotech ranks #310 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 65.5%.
Is Q-Line Biotech's Debt-to-EBITDA too high?
Q-Line Biotech's current Debt-to-EBITDA of 2.57 is near median its 10-year median of 2.40. Over the past 10 years, this metric has ranged from a low of 2.10 to a high of 2.57. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Q-Line Biotech's value of 2.57 is 56.7% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #310 out of 473 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #310 out of 473 companies for Debt-to-EBITDA. This places Q-Line Biotech in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Q-Line Biotech's value of 2.57 is 56.7% above this benchmark. Historically, Q-Line Biotech's own Debt-to-EBITDA has ranged from 2.10 to 2.57 over the past decade. While the company's 10-year median is 2.40 vs. the industry median of 1.64, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Debt-to-EBITDA of 2.57 is 56.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Q-Line Biotech. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Debt-to-EBITDA is 2.57, which is near median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Debt-to-EBITDA of 2.57. The current Debt-to-EBITDA is 2.57, which is near median its 10-year median of 2.40 and 56.7% above the Medical Devices & Instruments industry median of 1.64. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Debt-to-EBITDA is 2.57 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score
Get the complete analysis for NSE:QLINE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 
